---
document_datetime: 2025-12-03 15:38:59
document_pages: 2
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/cancidas-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: cancidas-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 1.286001
conversion_datetime: 2025-12-27 13:21:47.783988
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Cancidas

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency`s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, you may need to also refer to EPAR - Procedural steps taken and scientific information after authorisation (archive) .

| Application number         | Scope                                                                                                              | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------------|--------------------------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| PSUR / EMA/PSUR/0000268976 | In view of available data on caspofungin treatment failure during continuous renal replacement therapy (CRRT) with | 18/09/2025                          | 17/11/2025                                  | SmPC                             | Variation |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

|                                  | polyacrylonitrile (PAN) membranes from the literature, spontaneous reports (including in five cases a close temporal relationship and fatal outcomes), and in view of a plausible mechanism of action (adsorption of the free drug fraction by PAN membranes leading to subtherapeutic exposure), the PRAC considers a causal relationship between caspofungin and treatment failure during CRRT with PAN membranes is at least a reasonable possibility. The PRAC concluded that the product information of products containing caspofungin should be amended accordingly.   |            |            |    |
|----------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----|
| Article 61(3) / EMA/N/0000266529 | - Notification acc. Article 61(3) - Accepted Update of the package leaflet with revised contact details of local representatives and to delete 'United Kingdom (Northern Ireland)' from the list of local representatives in line with the QRD template v10.4. Additionally, the MAH took the opportunity to make minor editorial changes in some of the translations.                                                                                                                                                                                                        | 24/04/2025 | 17/11/2025 | PL |